يعرض 1,741 - 1,760 نتائج من 19,608 نتيجة بحث عن '(( significant ((all decrease) OR (a decrease)) ) OR ( significantly increased decrease ))', وقت الاستعلام: 0.73s تنقيح النتائج
  1. 1741
  2. 1742
  3. 1743
  4. 1744

    Flow chart of experimental protocol. حسب Eun-Seon Yang (19751340)

    منشور في 2024
    الموضوعات:
  5. 1745

    Table 2_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx حسب Jinyu He (19774641)

    منشور في 2025
    "…However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I<sup>2</sup> = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I<sup>2</sup> = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I<sup>2</sup> = 0.0%), and potentially increased incidence of composite renal outcomes.…"
  6. 1746

    Table 1_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx حسب Jinyu He (19774641)

    منشور في 2025
    "…However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I<sup>2</sup> = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I<sup>2</sup> = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I<sup>2</sup> = 0.0%), and potentially increased incidence of composite renal outcomes.…"
  7. 1747

    Table 3_To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure.docx حسب Jinyu He (19774641)

    منشور في 2025
    "…However, MRA therapy was associated with an increased risk of renal dysfunction, including hyperkalemia (RR = 2.086, 95% CI: 1.872–2.325, p < 0.001; I<sup>2</sup> = 0.0%), elevated serum creatinine (RR = 1.512, 95% CI: 1.252–1.825, p < 0.001; I<sup>2</sup> = 0.0%), decreased eGFR (WMD = −5.223, 95% CI: −7.380 to −3.066, p < 0.001; I<sup>2</sup> = 0.0%), and potentially increased incidence of composite renal outcomes.…"
  8. 1748
  9. 1749
  10. 1750
  11. 1751
  12. 1752
  13. 1753
  14. 1754

    Enterocolitis severity increases with DSS concentration. حسب Cuilee Sha (4836888)

    منشور في 2025
    "…<b>(D)</b> Cellular proliferation, as measured by number of Ki67-<i>p</i>ositive cells within small intestinal crypts, decreased significantly in 2% DSS. One-way ANOVA with Tukey’s post-hoc, p < 0.0001 (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0323626#pone.0323626.s018" target="_blank">S10</a> and <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0323626#pone.0323626.s019" target="_blank">S11 Tables</a>). …"
  15. 1755

    Establishment of a diabetic rat model. حسب Lan Zeng (638254)

    منشور في 2025
    "…Accordingly, we measured VEGF gene expression and found that it was significantly increased in the retinas of diabetic rats (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0312791#pone.0312791.g003" target="_blank">Fig 3A</a>). …"
  16. 1756
  17. 1757
  18. 1758
  19. 1759
  20. 1760